ASPEN PHARMACARE HOLDINGS LIMITED - Italian Court14 Jun 2017
APN 201706140069A
Italian Court Ruling on Appeal – Oncology Products

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen”)



ITALIAN COURT RULING ON APPEAL – ONCOLOGY PRODUCTS

Aspen Holdings has been informed that the Italian Court has dismissed Aspen’s appeal against the
Italian Competition Authority (“ICA”) ruling relating to Aspen’s portfolio of oncology products
distributed in Italy. The effect of this is that Aspen will be obliged to now pay the fine imposed by
the ICA in the amount of €5.2 million, plus interest thereon.

Aspen has noted the abridged principle judgment of the Italian Court announced earlier today and is
awaiting the release of the full reasons for that judgment and the Italian Court’s assessment of the
underlying facts, including that:
   - prices for most of the relevant Aspen drugs in Italy had not been increased for between 40
     and 60 years; and
   - a generic version of one of the Aspen drugs in question has recently been approved in Italy
     with a list price of more than double that of the Aspen drug on an equivalent dose basis.

The reasons for the judgment will be handed down in due course. Aspen will engage its advisers and
consider the matter further against receipt of those reasons, including Aspen’s automatic right to
lodge a further appeal to the “Council of State” appeal court.

Durban
14 June 2017


Sponsor:
Investec Bank Limited


About Aspen

Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive
basket of products that provide treatment for a broad spectrum of acute and chronic conditions
experienced through all stages of life. Aspen continues to increase the number of lives benefitting
from its products, reaching more than 150 countries.

Aspen has a strong presence in both emerging and developed countries. Its emerging market
footprint includes Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe and the
Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a
developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and
has a growing presence in other developed countries, most notably in Western Europe.
Aspen operates with an established business presence in approximately 50 countries spanning 6
continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities
across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent
global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are
scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-
solids, steriles, biologicals, APIs and infant nutritionals.

Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical
company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies
on this exchange. For more information visit: http://www.aspenpharma.com/

Date: 14/06/2017 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.